LIVIVO - Search results -

Search results

Result 1 - 10 of total 31

Search options

Article ; Online: Prevalence of various forms of peripheral neuropathy in patients with systemic connective tissue diseases

Đurić Vanja / Stamenković Bojana / Petković Ivan / Đurić Luka

Vojnosanitetski Pregled, Vol 80, Iss 7, Pp 561-

A clinical and electrophysiological study

2023 Volume 569

Abstract: Background/Aim. Peripheral neuropathy (PN) in systemic connective tissue diseases (SCTDs) represents the apparent disease complications or initial manifestations of clinically undiagnosed conditions. The aim of the study was to identify neuropathies (Ns) ...

Abstract	Background/Aim. Peripheral neuropathy (PN) in systemic connective tissue diseases (SCTDs) represents the apparent disease complications or initial manifestations of clinically undiagnosed conditions. The aim of the study was to identify neuropathies (Ns) and their prevalence, point out the diagnostic significance of some electrophysiological (EP) parameters in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and systemic sclerosis (SSc), and establish their association with disease activity (DA) and disease duration (DDu). Methods. A prospective study was conducted at the Rheumatology Clinic of the Institute for Treatment and Rehabilitation “Niška Banja” over a three-year period. The study included 157 patients in total, of whom 61 had R A, 4 0 had SLE, and 56 had SSc. The following parameters were analyzed: age, gender, DDu, course of the disease, and DA index. Moreover, clinical, rheumatological, and neurological examinations, as well as neurology tests, nerve conduction studies (NCS), and laboratory analyses, were also conducted. Results. In the studied population, we were able to identify various forms of Ns (in 28.7% of patients) by NCS. In all three groups, the most prevalent type of Ns was axonal (23.6%), sensorimotor (18.5%), and polyneuropathy (23.6%). There was a significant association between DA and the occurrence of Ns (p < 0.001) in the total population. The most important EP parameter was the sensory nerve action potential amplitude of nervus peroneus superficialis [in 70 (44.6%) patients] and nervus suralis [in 35 (22.3%) patients], and compound muscle action potential amplitude of nervus peroneus [in 32 (20.4%) patients]. DDu in all three groups was longer in the population of patients with Ns. Conclusion. Ns are most common in patients with longer DDu and higher DA. The EP method is important in detecting Ns, especially in the early detection of subclinical forms of Ns and the prevention of disease complications.
Keywords	arthritis ; rheumatoid ; autoimmune diseases ; connective tissue ; diagnosis ; lupus erythematosus ; systemic ; peripheral nervous system diseases ; scleroderma ; Medicine (General) ; R5-920
Subject code	610
Language	English
Publishing date	2023-01-01T00:00:00Z
Publisher	Military Health Department, Ministry of Defance, Serbia
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Prognostic Value of Lactate Dehydrogenase in Patients with Melanoma Treated with Pembrolizumab.

Popović, Aleksandar / Petković, Ivan / Dimitrijevic, Aleksandra / Jović, Andrija

Acta dermatovenerologica Croatica : ADC

2023 Volume 31, Issue 2, Page(s) 86–91

Abstract: Introduction: Elevated LDH levels have been extensively reported as a biomarker of poorer outcome in patients with melanoma during the chemotherapeutic era. The role of LDH level as a prognostic factor for treatment outcomes in patients with metastatic ... ...

Abstract	Introduction: Elevated LDH levels have been extensively reported as a biomarker of poorer outcome in patients with melanoma during the chemotherapeutic era. The role of LDH level as a prognostic factor for treatment outcomes in patients with metastatic melanoma treated with immunooncological therapy has also been reported but requires further analysis. Objectives: In this study, we aimed to evaluate the prognostic value of lactate dehydrogenase (LDH) among patients with metastatic and unresectable melanoma treated with pembrolizumab in terms of progression-free survival (PFS). Methods: The study included 59 patients with unresectable and metastatic melanoma treated with pembrolizumab. A comparison was performed between patients with normal and elevated levels of LDH in terms of PFS, with subgroup analysis. Results: There was a significant reduction in PFS among patients with elevated levels of LDH compared with patients with normal levels of LDH (NR vs. 5 months; P=0.02). Patients with elevated LDH levels were older (P=0.01), with liver metastasis (P=0.004), and with less frequent CNS deposits (P=0.028). Conclusion: Although novel agents improved outcomes in patients with melanoma, high levels of LDH persist as an independent prognostic biomarker of poor prognosis.
MeSH term(s)	Humans ; Prognosis ; Skin Neoplasms/pathology ; L-Lactate Dehydrogenase/therapeutic use ; Retrospective Studies ; Melanoma/pathology ; Biomarkers
Chemical Substances	pembrolizumab (DPT0O3T46P) ; L-Lactate Dehydrogenase (EC 1.1.1.27) ; Biomarkers
Language	English
Publishing date	2023-09-25
Publishing country	Croatia
Document type	Journal Article
ZDB-ID	1180727-1
ISSN	1847-6538 ; 1330-027X
ISSN (online)	1847-6538
ISSN	1330-027X
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3934: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Current trends in the treatment of primary mediastinal large B-cell lymphoma - an overview.

Petković, Ivan

Contemporary oncology (Poznan, Poland)

2015 Volume 19, Issue 6, Page(s) 428–435

Abstract: Primary mediastinal large B-cell lymphoma has been recognised as a distinct entity with unique clinical, pathologic, and genetic features. According to WHO 2008 classification it is marked as a variant of diffuse large B-cell lymphoma but shares ... ...

Abstract	Primary mediastinal large B-cell lymphoma has been recognised as a distinct entity with unique clinical, pathologic, and genetic features. According to WHO 2008 classification it is marked as a variant of diffuse large B-cell lymphoma but shares characteristics with classic Hodgkin lymphoma. Genetic analysis has shown that amplification of the 9p24.1 region is the disease's specific structural alteration. Aggressive behaviour and a tendency to invade surrounding tissues of the thoracic cavity, often causing superior vena cava syndrome, or pleural or pericardial effusions, are the clinical hallmarks of this disease. For a long period of time it has been considered as a disease with poor prognosis, which responds poorly to the conventional treatment created for diffuse large B-cell lymphoma. An elective treatment has not yet been established, but recently the situation has became much more favourable. After the introduction of rituximab the cure rates have risen to over 80%, and the most recent results have demonstrated a new insight with dose-adjusted intensified continuous treatments, in which the cure rates have exceeded 90%. Current trends have led to the introduction of dose-adjusted intensified protocols becoming a standard of care, whereas the use of radiotherapy remains controversial because of the questionable predictive value of post-treatment PET/CT validity. The relapse rate is very low after two years of sustained complete remission. If the disease relapses or is resistant the outcome is very poor regardless of the applied treatment modality.
Language	English
Publishing date	2015-12-16
Publishing country	Poland
Document type	Journal Article ; Review
ISSN	1428-2526
ISSN	1428-2526
DOI	10.5114/wo.2015.56388
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Pathologic complete response in metastatic right-sided colon cancer treated with panitumumab and FOLFOX4 chemotherapy regimen

Džunić Miljana / Cvetanović Ana / Petković Ivan / Todorović-Stojanović Ivana

Srpski Arhiv za Celokupno Lekarstvo, Vol 150, Iss 11-12, Pp 716-

2022 Volume 720

Abstract: Introduction. Recommended biological agents for the first-line treatment of left-sided metastatic colorectal cancer (mCRC) without mutations in RAS/BRAF genes are cetuximab or panitumumab, while for rightsided mCRC bevacizumab is advised instead. For ... ...

Abstract	Introduction. Recommended biological agents for the first-line treatment of left-sided metastatic colorectal cancer (mCRC) without mutations in RAS/BRAF genes are cetuximab or panitumumab, while for rightsided mCRC bevacizumab is advised instead. For transversal colon mCRC the data about biological treatment efficacy is lacking. We present a patient with right-sided mCRC originated from transversal colon where panitumumab and chemotherapy treatment resulted in an excellent outcome. Case outline. A 56-year-old woman was diagnosed with transversal colon adenocarcinoma, without RAS genes mutations, with multiple liver metastases disseminated in both lobes. After the operation of the primary tumor, the patient was treated with panitumumab and FOLFOX4 chemotherapy regimen. After two months of treatment, the dramatic response was evident – The diameter sum of the target lesions decreased by 70.5%. After two more months of therapy, further decrease by 22.5% was evident. Liver metastases were operated on. Histopathology revealed fibrotic and necrotic tissue in all suspicious lesions, except in one focus, where adenocarcinoma was found, but with 90% of surrounding necrosis. Twelve months after liver surgery the patient is without signs of the progressive disease. Conclusion. Detailed comprehensive studies of genetic features of mCRC hold a key to personalized treatment options and better outcomes for patients with mCRC.
Keywords	colorectal cancer ; panitumumab ; transversal colon ; liver metastases ; Medicine ; R
Subject code	610 ; 616
Language	English
Publishing date	2022-01-01T00:00:00Z
Publisher	Serbian Medical Society
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: EBV Negative Angioimmunoblastic T-Cell Lymphoma with Sequential Development of Diffuse Large B-Cell Lymphoma in Course of Progression.

Petković, Ivan / Stojnev, Slavica / Popović, Aleksandar / Krstić, Miljan / Pejčić, Ivica

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion

2021 Volume 37, Issue 4, Page(s) 694–696

Language	English
Publishing date	2021-03-25
Publishing country	India
Document type	Journal Article
ZDB-ID	2422370-0
ISSN	0974-0449 ; 0971-4502
ISSN (online)	0974-0449
ISSN	0971-4502
DOI	10.1007/s12288-021-01425-w
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article ; Online: Single Center Experience Study with Pembrolizumab in Patients with BRAF Mutant Negative Metastatic Melanoma

Pejčić Ivica / Petković Ivan / Cvetanović Ana / Conić Irena

Acta Facultatis Medicae Naissensis, Vol 35, Iss 4, Pp 267-

2018 Volume 272

Abstract: The aim of the paper was to determine the efficacy, toxicity and progression free survival with anti-PD-1 immunotherapy pembrolizumab in BRAF wild type metastatic melanoma patients with good performance status (ECOG PS 0-1). From February 2017 to April ... ...

Abstract	The aim of the paper was to determine the efficacy, toxicity and progression free survival with anti-PD-1 immunotherapy pembrolizumab in BRAF wild type metastatic melanoma patients with good performance status (ECOG PS 0-1). From February 2017 to April 2018, 17 patients with BRAF mutant wild type metastatic melanoma were enrolled in the study. Only 3/17 patient had received chemotherapy previously. The aim of the study was to confirm the efficacy of pembrolizumab immunotherapy in patients with good performance status (ECOG 0-1). Treatment consisted of pembrolizumab 2 mg/kg Q3 weeks continued until disease progression or intolerable toxicity. Secondary end points included toxicity and progression-free survival (defined as the time from randomization to documented disease progression according to RECIST). The overall response rate (ORR) was 11/17 (53.0 %), with complete response (CR) 0, partial response (PR) 3 (18 %), stable disease (SD) 8 (47%), and progressive disease (PD) 6 (35%). A total number of 97 consecutive cycles were administered. Adverse effects were mild. The most common toxicity was pneumonitis grade 1. None of the patients in the study demonstrated grade 2, 3 and 4 toxicity. No treatment-related deaths occurred. The median time to disease progression was 5.8 months. Anti-PD-1 pembrolizumab immunotherapy appeared to be a beneficial therapeutic approach with less toxicity for metastatic BRAF wild type melanoma patients with good PS.
Keywords	immunotherapy ; pembrolizumab ; metastatic melanoma ; Medicine ; R
Subject code	610
Language	English
Publishing date	2018-12-01T00:00:00Z
Publisher	Sciendo
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: PEPP-Entgeltsystem 2019 und DKR-Psych

Petkovic, Ivan / Schlottmann, Nicole

Das Krankenhaus

2018 Volume 110, Issue 12, Page(s) 1189

Language	German
Document type	Article
ZDB-ID	3262-1
ISSN	0340-3602
Database	Current Contents Medicine

In stock of ZB MED Cologne/Königswinter

Ue I Zs.30: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Current and future targets and therapies in metastatic colorectal cancer.

Dzunic, Miljana / Petkovic, Ivan / Cvetanovic, Ana / Vrbic, Svetislav / Pejcic, Ivica

Journal of B.U.ON. : official journal of the Balkan Union of Oncology

2019 Volume 24, Issue 5, Page(s) 1785–1792

Abstract: Colorectal cancer (CRC) is the third most common cancer and the second cause of cancer-related deaths worldwide. Despite early diagnosis and treatment improvement, the majority of patients will still suffer from metastatic disease (mCRC), which has a ... ...

Abstract	Colorectal cancer (CRC) is the third most common cancer and the second cause of cancer-related deaths worldwide. Despite early diagnosis and treatment improvement, the majority of patients will still suffer from metastatic disease (mCRC), which has a poor prognosis. Molecular diversity of CRC requires personalized targeted approach for improving patient outcomes. Antiangiogenic agents proved to be beneficial in the continuum of mCRC treatment. For efficient epidermal growth factor receptor (EGFR) directed therapy, subtle molecular selection and better strategies to overcome resistance are needed. BRAF mutant and HER-2 positive mCRC will soon be provided with approved targeted treatments and check-point inhibitors demonstrated effectiveness in microsatellite instability (MSI) - high mCRC. Moreover, numeorous promising agents are entering clinical trial arena. This review summarizes actual and possible targets and current and promising agents for mCRC treatment. With broader accessibility of liquid biopsy we could track molecular evolution of CRC and target genetic alterations as they emerge.
MeSH term(s)	Animals ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/metabolism ; Colorectal Neoplasms/pathology ; Drug Design ; Drug Resistance, Neoplasm ; Gene Expression Regulation, Neoplastic ; Humans ; Molecular Targeted Therapy ; Neoplasm Metastasis ; Signal Transduction
Chemical Substances	Antineoplastic Agents ; Biomarkers, Tumor
Language	English
Publishing date	2019-11-30
Publishing country	Greece
Document type	Journal Article ; Review
ZDB-ID	2040386-0
ISSN	2241-6293 ; 1107-0625
ISSN (online)	2241-6293
ISSN	1107-0625
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5438: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Proteasome inhibitors

Petković Ivan / Pejčić Ivica / Vrbić Svetislav

Racionalna Terapija, Vol 8, Iss 2, Pp 25-

A rational for clinical use in the treatment of multiple myeloma

2016 Volume 33

Abstract: Proteasome inhibitors (PI) represent the class of medicaments which lead to inhibition of catalytic chymotrypsin-like proteolytic proteasome subunits. Blockade of this specific structure drives to complete ubiquitin-proteasome machinery withdrawal. Total ...

Abstract	Proteasome inhibitors (PI) represent the class of medicaments which lead to inhibition of catalytic chymotrypsin-like proteolytic proteasome subunits. Blockade of this specific structure drives to complete ubiquitin-proteasome machinery withdrawal. Total intracellular protein flow is regulated by the proteasome activity which acts through basal and signal activated proteolysis as the result of cell stimuli. Blockade of proteasome activity contribute to cell protein hyper concentration which results with activation of cell death mechanisms. This is primary endpoint of PI activity against the cancer cell. Multiple myeloma (MM) represents the second most frequent blood cancer. The backbone of therapy constitute of triple-combination of long-acting corticosteroid (dexamethason), imunomodulatory drugs (IMiDs), such as thalidomide, lenalidomideorpomalidomide, and PI. Treatment strategy involves the use of induction therapy, after which, if disease is sensitive, high dose therapy should be followed by autologous hematopoietic stem cell transplantation. The above-mentioned treatment modality is reserved for younger patients (≤65 years), while elderly have medical treatment without transplantation. Whether maintenance therapy should be applied after remission is achieved, remains a matter of great controversy, although many centers apply it as 'off label' use. Reversible PIs include: bortezomib and ixazomib, and irreversible PI include: carfilzomib, oprozomib and marizomib. These drugs are found to have tolerable safety profile with the accent on peripheral neuropathy, gastrointestinal and moderate hematological toxicityas the most usual adverse events. This article will consider clinical pharmacology of PIs.
Keywords	proteasome ; proteasome inhibitors ; multiple myeloma ; rational therapy ; Medicine (General) ; R5-920
Subject code	610
Language	English
Publishing date	2016-01-01T00:00:00Z
Publisher	Medicinsko društvo za racionalnu terapiju Republike Srbije
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: PEPP-Entgeltsystem 2018 und DKR-Psych

Schlottmann, Nicole / Petkovic, Ivan

Das Krankenhaus

2017 Volume 109, Issue 11, Page(s) 966

Language	German
Document type	Article
ZDB-ID	3262-1
ISSN	0340-3602
Database	Current Contents Medicine

In stock of ZB MED Cologne/Königswinter

Ue I Zs.30: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito